Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 1/2008

01.02.2008

Dietary supplements, herbs and oral anticoagulants: the nature of the evidence

verfasst von: Ann K. Wittkowsky

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

In the US, the use of dietary supplements, including vitamins, minerals, amino acids, and herbal products, is extensive. Nonetheless, the majority of patients report that they have little information about the risks, benefits, and adverse effects of medicines, or about their potential interactions with prescription drugs. Patients taking warfarin are at particular risk of interactions with dietary supplements, yet approximately 30% use herbal or natural product supplements on a regular basis. No current governmental regulations or voluntary programs address dietary supplement interactions with prescription drugs. Case reports represent the majority of the evidence surrounding drug interactions between warfarin and dietary supplements. Those of the highest quality include, as an assessment of causality, a modification of the recently published Drug Interaction Probability Scale. Despite positive case reports, formal drug interaction studies are often negative, suggesting that numerous patient-specific influences other than the suspected interaction alone may be responsible for a particular observation. The cranberry-juice/warfarin interaction is a recent example of such a discrepancy. Healthcare providers can play an active role in improving quantity and the quality of case reports of interactions involving warfarin and dietary supplements. A registry of anticoagulant interactions with dietary supplements has been proposed, and is currently being developed through Clotcare Online Resource (http://​www.​clotcare.​com). The goal of this registry is to obtain high quality case-based evidence of drug interactions between anticoagulants and dietary supplements, to define these interactions based on clinical and monitoring outcomes, and to analyze likelihood of causation using a modification of the Drug Interaction Probability Scale.
Literatur
1.
Zurück zum Zitat Eisenberg DM, Davis RB, Ettner SL et al (1998) Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280:1569–1575PubMedCrossRef Eisenberg DM, Davis RB, Ettner SL et al (1998) Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280:1569–1575PubMedCrossRef
2.
Zurück zum Zitat Barnes PM, Powell-Griner E, McFann K, Nahin RL (2004) Complimentary and alternative medicine use among adults. United States, 2002. Adv Data 343:1–19PubMed Barnes PM, Powell-Griner E, McFann K, Nahin RL (2004) Complimentary and alternative medicine use among adults. United States, 2002. Adv Data 343:1–19PubMed
3.
Zurück zum Zitat Gunther S, Patterson RE, Kristal AR et al (2004) Demographic and health-related correlates of herbal and specialty supplement use. J Am Diet Assoc 104:27–34PubMedCrossRef Gunther S, Patterson RE, Kristal AR et al (2004) Demographic and health-related correlates of herbal and specialty supplement use. J Am Diet Assoc 104:27–34PubMedCrossRef
4.
Zurück zum Zitat Wood MJ, Stewart RL, Merry H et al (2003) Use of complementary and alternative medical therapies in patients with cardiovascular disease. Am Heart J 145:806–812PubMedCrossRef Wood MJ, Stewart RL, Merry H et al (2003) Use of complementary and alternative medical therapies in patients with cardiovascular disease. Am Heart J 145:806–812PubMedCrossRef
5.
Zurück zum Zitat Chagan L, Bernstein D, Cheng JW et al (2005) Use of biological based therapy in patients with cardiovascular diseases in a university-hospital in New York City. BMC Complement Altern Med 5:4–13PubMedCrossRef Chagan L, Bernstein D, Cheng JW et al (2005) Use of biological based therapy in patients with cardiovascular diseases in a university-hospital in New York City. BMC Complement Altern Med 5:4–13PubMedCrossRef
6.
Zurück zum Zitat Holbrook AM, Pereira JA, Labiris R et al (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165:1095–1106PubMedCrossRef Holbrook AM, Pereira JA, Labiris R et al (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165:1095–1106PubMedCrossRef
7.
Zurück zum Zitat Nutescu EA, Shapiro NL, Ibrahim S, West P (2006) Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf 5:433–451PubMedCrossRef Nutescu EA, Shapiro NL, Ibrahim S, West P (2006) Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf 5:433–451PubMedCrossRef
8.
Zurück zum Zitat Wong RS, Cheng G, Chan TY (2003) Use of herbal medicinals by patients receiving warfarin. Drug Saf 26:585–588PubMedCrossRef Wong RS, Cheng G, Chan TY (2003) Use of herbal medicinals by patients receiving warfarin. Drug Saf 26:585–588PubMedCrossRef
9.
Zurück zum Zitat Ramsay NA, Kenny MW, Davies G, Patel JP (2005) Complimentary and alternative medicine use among patients starting warfarin. Br J Haematol 130:777–780PubMedCrossRef Ramsay NA, Kenny MW, Davies G, Patel JP (2005) Complimentary and alternative medicine use among patients starting warfarin. Br J Haematol 130:777–780PubMedCrossRef
10.
Zurück zum Zitat Smith L, Ernst E, Ewings P et al (2004) Co-ingestion of herbal medicines and warfarin. Br J Gen Practice 54:439–441 Smith L, Ernst E, Ewings P et al (2004) Co-ingestion of herbal medicines and warfarin. Br J Gen Practice 54:439–441
11.
Zurück zum Zitat Zuckerman IH, Steinberger EK, Ryder P, Haines S (2002) Herbal product use among anticoagulation clinic patients. Am J Health-Syst Pharm 59:379–380PubMed Zuckerman IH, Steinberger EK, Ryder P, Haines S (2002) Herbal product use among anticoagulation clinic patients. Am J Health-Syst Pharm 59:379–380PubMed
12.
Zurück zum Zitat Wittkowsky AK, Bussey HI, Walker MB, Frei CR (2007) Dietary supplement use among anticoagulation clinic patients. J Thromb Haemost 5:875–877PubMedCrossRef Wittkowsky AK, Bussey HI, Walker MB, Frei CR (2007) Dietary supplement use among anticoagulation clinic patients. J Thromb Haemost 5:875–877PubMedCrossRef
13.
Zurück zum Zitat Noonan C, Noonan WP (2006) Marketing dietary supplements in the United States: a review of the requirements for new dietary ingredients. Toxicology 221:4–8PubMedCrossRef Noonan C, Noonan WP (2006) Marketing dietary supplements in the United States: a review of the requirements for new dietary ingredients. Toxicology 221:4–8PubMedCrossRef
14.
Zurück zum Zitat Srinivasan VS (2006) Challenges and scientific issues in the standardization of botanicals and their preparations. United States Pharmacopeia’s dietary supplement verification program—a public health program. Life Sci 78:2039–2043PubMedCrossRef Srinivasan VS (2006) Challenges and scientific issues in the standardization of botanicals and their preparations. United States Pharmacopeia’s dietary supplement verification program—a public health program. Life Sci 78:2039–2043PubMedCrossRef
15.
Zurück zum Zitat Huang SM, Temple R, Throckmorton DC, Lesko LJ (2007) Drug interaction studies: study design, data analysis and implications for dosing and labeling. Nature 81:298–304 Huang SM, Temple R, Throckmorton DC, Lesko LJ (2007) Drug interaction studies: study design, data analysis and implications for dosing and labeling. Nature 81:298–304
16.
Zurück zum Zitat Aronson JK (2005) Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions. J Eval Clin Pract 11:195–208PubMedCrossRef Aronson JK (2005) Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions. J Eval Clin Pract 11:195–208PubMedCrossRef
17.
Zurück zum Zitat Kelly WN (2003) The quality of published adverse drug event reports. Ann Pharmcotherapy 37:1774–1778CrossRef Kelly WN (2003) The quality of published adverse drug event reports. Ann Pharmcotherapy 37:1774–1778CrossRef
18.
Zurück zum Zitat Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245PubMedCrossRef Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245PubMedCrossRef
19.
Zurück zum Zitat Horn JR, Hansten PD, Chan LN (2007) Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacotherapy 41:674–680CrossRef Horn JR, Hansten PD, Chan LN (2007) Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacotherapy 41:674–680CrossRef
20.
Zurück zum Zitat Suvarna R, Pimrohamed M, Henderson L (2003) Possible interaction between warfarin and cranberry juice. BMJ 327:1454PubMedCrossRef Suvarna R, Pimrohamed M, Henderson L (2003) Possible interaction between warfarin and cranberry juice. BMJ 327:1454PubMedCrossRef
22.
Zurück zum Zitat Grant P (2004) Warfarin and cranberry juice. An interaction? J Heart Valv Dis 13:25–26 Grant P (2004) Warfarin and cranberry juice. An interaction? J Heart Valv Dis 13:25–26
23.
Zurück zum Zitat Rindone JP, Murphy TW (2006) Warfarin-cranberry juice interaction resulting in profound hypoprothrombininemia and bleeding. Am J Ther 13:283–284PubMedCrossRef Rindone JP, Murphy TW (2006) Warfarin-cranberry juice interaction resulting in profound hypoprothrombininemia and bleeding. Am J Ther 13:283–284PubMedCrossRef
24.
Zurück zum Zitat Aston JL, Lodolce AE, Shapiro NL (2006) Interaction between warfarin and cranberry juice. Pharmacotherapy 26:1314–1319PubMedCrossRef Aston JL, Lodolce AE, Shapiro NL (2006) Interaction between warfarin and cranberry juice. Pharmacotherapy 26:1314–1319PubMedCrossRef
25.
Zurück zum Zitat Hodek P, Trefil P, Stiborova M (2002) Flavenoids: potent and versatile biologically active compounds interacting with cytochrome P450. Chem Biol Interact 139:1–21PubMedCrossRef Hodek P, Trefil P, Stiborova M (2002) Flavenoids: potent and versatile biologically active compounds interacting with cytochrome P450. Chem Biol Interact 139:1–21PubMedCrossRef
26.
Zurück zum Zitat Committee on Safety of Medicines, Medicines and Healthcare Products Regulatory Agency (2004) Interaction between warfarin and cranberry juice: new advice. Current Problems in Pharmacovigilance 30:10 Committee on Safety of Medicines, Medicines and Healthcare Products Regulatory Agency (2004) Interaction between warfarin and cranberry juice: new advice. Current Problems in Pharmacovigilance 30:10
27.
Zurück zum Zitat Greenblatt DJ, von Moltke LL, Perloff ES et al (2006) Interaction of flurbiprofen with cranberry juice, grape juice, tea and fluconazole. In vitro and clinical studies Clin Pharmacol Ther 79:125–133PubMedCrossRef Greenblatt DJ, von Moltke LL, Perloff ES et al (2006) Interaction of flurbiprofen with cranberry juice, grape juice, tea and fluconazole. In vitro and clinical studies Clin Pharmacol Ther 79:125–133PubMedCrossRef
28.
Zurück zum Zitat Grenier J, Fradette C, Morelli G et al (2006) Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans. Clin Pharmacol Ther 79:255–262PubMedCrossRef Grenier J, Fradette C, Morelli G et al (2006) Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans. Clin Pharmacol Ther 79:255–262PubMedCrossRef
29.
Zurück zum Zitat Lilja JJ, Backman JT, Neuvonen PJ (2007) Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine and midazolam probes of CYP2C9, CYP1A2, and CYP3A4. Clin Pharmacol Ther; in press Lilja JJ, Backman JT, Neuvonen PJ (2007) Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine and midazolam probes of CYP2C9, CYP1A2, and CYP3A4. Clin Pharmacol Ther; in press
30.
Zurück zum Zitat Zhaoping LI, Seerman NP, Carpenter CL et al (2006) Cranberry does not affect prothrombin time in male subjects on warfarin. J Am Diet Assoc 106:2057–2061CrossRef Zhaoping LI, Seerman NP, Carpenter CL et al (2006) Cranberry does not affect prothrombin time in male subjects on warfarin. J Am Diet Assoc 106:2057–2061CrossRef
31.
Zurück zum Zitat Foti RS, Wahlstrom JL, Wienkers LC (2007) The in vitro drug interaction potential of dietary supplements containing multiple herbal components. Drug Metab Disp 35:185–188CrossRef Foti RS, Wahlstrom JL, Wienkers LC (2007) The in vitro drug interaction potential of dietary supplements containing multiple herbal components. Drug Metab Disp 35:185–188CrossRef
32.
Zurück zum Zitat Zhu YP, Woerdenbag HJ (1995) Traditional Chinese herbal medicine. Pharm World Sci 17:103–112PubMedCrossRef Zhu YP, Woerdenbag HJ (1995) Traditional Chinese herbal medicine. Pharm World Sci 17:103–112PubMedCrossRef
33.
Zurück zum Zitat Tai MW, Sweet BV (2006) Nattokinase for prevention of thrombosis. Am J Health Syst Pharm 63:1121–1123PubMedCrossRef Tai MW, Sweet BV (2006) Nattokinase for prevention of thrombosis. Am J Health Syst Pharm 63:1121–1123PubMedCrossRef
34.
Zurück zum Zitat Cesarone MR, Belcaro G, Nicolaides AN et al (2003) Prevention of venous thrombosis in long-haul flights with Flite Tabs: the LONFLIT-FLITE randomized controlled trial. Angiology 54:531–539PubMedCrossRef Cesarone MR, Belcaro G, Nicolaides AN et al (2003) Prevention of venous thrombosis in long-haul flights with Flite Tabs: the LONFLIT-FLITE randomized controlled trial. Angiology 54:531–539PubMedCrossRef
35.
Zurück zum Zitat Bussey HI, Tapson V, Cannon RO 3rd, Nolan PE Jr et al (2005) NIH conference on dietary supplements, session V: opinions and research priorities. Thromb Res 117:155–169PubMedCrossRef Bussey HI, Tapson V, Cannon RO 3rd, Nolan PE Jr et al (2005) NIH conference on dietary supplements, session V: opinions and research priorities. Thromb Res 117:155–169PubMedCrossRef
Metadaten
Titel
Dietary supplements, herbs and oral anticoagulants: the nature of the evidence
verfasst von
Ann K. Wittkowsky
Publikationsdatum
01.02.2008
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 1/2008
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-007-0110-0

Weitere Artikel der Ausgabe 1/2008

Journal of Thrombosis and Thrombolysis 1/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.